Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Pawan Kumar Goel has a concentrated prosecution profile in the Biotechnology & Pharmaceuticals technology area. The portfolio currently features 1 pending office action situated in 1 distinct art unit. This reflects a singular technical focus for the current patenting activity.
The prosecution is overseen by 1 distinct examiner, BELL, SARA ELIZABETH, who is responsible for the 1 busiest examiner pending action. With only one examiner and one art unit involved, the prosecution process is very direct. The outcome of this single pending matter will determine the current status of the entity's patenting efforts.
Practitioners should note that the lack of examiner variety necessitates a highly targeted response strategy. Because there are no other active cases, the specific feedback from this examiner is the only guidance available for the current portfolio. Success in this environment depends on a clear and persuasive communication with the assigned art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BELL, SARA ELIZABETH | 1 | 68.8% | +38.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16983299 | HIGH PURITY ALPHA YOHIMBINE (RAUWOLSCINE) FROM RAUWOLFIA SPECIES | BELL, SARA ELIZABETH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16983299 | HIGH PURITY ALPHA YOHIMBINE (RAUWOLSCINE) FROM RAUWOLFIA SPECIES | BELL, SARA ELIZABETH | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 16983299 | HIGH PURITY ALPHA YOHIMBINE (RAUWOLSCINE) FROM RAUWOLFIA SPECIES | BELL, SARA ELIZABETH | 1625 | §101§103DP | Non-Final OA | — | Pending | Aug 03, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPawan Kumar Goel has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Sara Elizabeth Bell has the most, with 1 of Pawan Kumar Goel's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
